An observational study in Pneumococcal Vaccine, Esophageal Cancer and Lymphopenia, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · M.D. Anderson Cancer Center.
Among the 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center, this one is one of 2 that started in 2024, is one of 9 observational ones, and was the 27th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →5 of the 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 18–79
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9
First in 2000; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 200 across 433 observational studies indexed under Esophageal Neoplasms.
Median enrollment 56 across the 20 interventional studies, 80 across the 9 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
6 of the studies in Esophageal Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03161522M.D. Anderson Cancer CenterChemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | 2026-12-31 |
| NCT01512589M.D. Anderson Cancer CenterProton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial | 2027-04-30 |
| NCT03948100M.D. Anderson Cancer CenterDyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | 2027-04-30 |
| NCT04607590M.D. Anderson Cancer CenterYoga Program for Improving the Quality of Life in Couples Coping With Cancer | 2027-04-30 |
| NCT06181656M.D. Anderson Cancer CenterSerologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation | 2027-07-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To learn how radiation treatment may affect your responses to vaccines against pneumonia.
Primary Objectives
- Determine the impact of Grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination.
Secondary Objectives
MD Anderson Cancer Center will enroll 30 esophageal cancer patients. Massachusetts General Hospital in Boston, MA will enroll 30 HCC patients. MD Anderson Cancer Center \& Massachusetts General Hospital in Boston will jointly enroll up to 20 health volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1A
a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.
Group 1B
a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)
Group 2A
a. Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer.
Group 2B
a. Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer.
Group 3
a. Healthy age- and gender- matched individuals
All Groups
Exclusion Criteria:
Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy
a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer. This group will be subdivided into Group 1A, which will comprise 15 participants treated with proton therapy, and Group 1B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
Biological: Pneumonia vaccine
30 participants currently receiving, planning to receive, or recently completed chemoradiation for hepatocellular carcinoma. This group will be subdivided into Group 2A, which will comprise 15 participants treated with proton therapy, and Group 2B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
Biological: Pneumonia vaccine
20 Healthy Volunteers.
Biological: Pneumonia vaccine
Given by SC
Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination
Serologic responses will be calculated as the average fold change in antibody titer for each of 20 pneumococcal serotypes between baseline (time 0) and the first post-vaccination blood draw.
Time frame: through study completion; an average of 1 year
Started Feb 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.
Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 40 months is below that.
Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.